Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06915831 · ClinicalTrials.gov registry record · NA

Type 1 Diabetes and Obstructive Sleep Apnea

A NA study of Sleep Apnea, Obstructive and Type 1 Diabetes (T1D), sponsored by University of Chicago.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06915831 is a NA study of Sleep Apnea, Obstructive and Type 1 Diabetes (T1D) that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 40 participants, below the 261-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06915831, a NA study of Sleep Apnea, Obstructive and Type 1 Diabetes (T1D), is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to investigate the role of sleep apnea in glycemic dysregulation in adults with Type 1 diabetes.

Interventions

  • DEVICE Continuous positive airway pressure (CPAP)

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-11-10
Est. Completion 2029-08-31
Phase NA

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT06915831

The ClinicalTrials.gov registry entry for NCT06915831 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 45 other Sleep Apnea, Obstructive trials with a reported enrollment target (85% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sleep Apnea, Obstructive appearing as the primary indexed condition, and to 1 intervention - of which Continuous positive airway pressure (CPAP) is the first listed.

NCT06915831 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06915831 about?

NCT06915831 is a clinical study titled "Type 1 Diabetes and Obstructive Sleep Apnea". The purpose of the study is to investigate the role of sleep apnea in glycemic dysregulation in adults with Type 1 diabetes.

What is the current status of trial NCT06915831?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-11-10. Estimated completion is 2029-08-31.

What conditions does trial NCT06915831 study?

This clinical trial studies the following conditions: Sleep Apnea, Obstructive, Type 1 Diabetes (T1D).

What interventions are being tested in trial NCT06915831?

The interventions under investigation include: Continuous positive airway pressure (CPAP) (DEVICE).

Who is sponsoring clinical trial NCT06915831?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06915831 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Apnea, Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.